ImmPACT Bio Raises $111M For Its Next-Generation Cancer Cell Therapy
ImmPACT Bio was formed from a merger with Israeli company Immpact, which was raised in the FutuRX biotech incubator, and US company Kalthera.
Source: nocamels.com
Gideon Gross News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Gideon Gross. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Gideon Gross Today - Breaking & Trending Today
ImmPACT Bio Closes $111M Series B Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
/PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR)...
Source: prnewswire.com
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
/PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR)...
Source: prnewswire.com
ImmPACT Bio reels in $111M to prevent tumor escape with novel cell therapies
Despite the targeted approach of some cancer treatments, tumors can find ways to escape, leading patients to relapse. ImmPACT Bio will apply its Series B financing toward the development of cell therapies designed to prevent tumor escape.
Source: medcitynews.com